|Articles|August 2, 2006

Pharmaceutical Technology

  • Pharmaceutical Technology-08-02-2006
  • Volume 30
  • Issue 8

FDA Boosts User Fees 17-19% for FY 2007

The US Food and Drug Administration announced its Prescription Drug User Fee Amendments of 2002 (PDUFA II) fees schedule for fiscal year 2007 (Oct. 1, 2006 - Sept. 30, 2007), including increases ranging from 17% to 19%.

In an Aug. 2 Federal Register announcement (1), the US Food and Drug Administration (Rockville, MD, www.fda.gov) announced its Prescription Drug User Fee Amendments of 2002 (PDUFA III) fees for fiscal year 2007 (Oct. 1, 2006–Sept. 30, 2007). The new fee schedule for drug and biological products will be:

  • $896,200 for an application requiring clinical data, up 17% from $767,400 for FY 2006;
  • $448,100 for an application not requiring clinical data or a supplement requiring clinical data, up 17% from $383,700;
  • $313,100 for establishment fees, up 19% from $264,000;
  • $49,750 for product fees, up 18% from $42,130.

The agency will begin issuing invoices for establishment and product fees under the new schedule this month.

Reference

1. US Food and Drug Administration, "Prescription Drug User Fee Rates for Fiscal Year 2007," Federal Register 71 (148), 43780–43784 (Aug. 2, 2006). DOCID:fr02au06-96.

Articles in this issue

about 20 years ago

Schering Recalls Ultravist Injection

about 20 years ago

The Modern Soapbox

about 20 years ago

Reinventing FDA: A Mid-Course Report

about 20 years ago

Cracking Down on Counterfeiting

about 20 years ago

Our Readers Write In

about 20 years ago

China Just Around the Corner

about 20 years ago

August 2006

Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.